Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The transforming growth factor β (TGF-β) pathway acts as a double-edged sword in tumorigenesis. By constraining epithelial cell growth, TGF-β is a potent tumor suppressor. However, TGF-β also acts as a key player in the induction of epithelial-to-mesenchymal transition (EMT), thereby enhancing invasiveness and metastasis. Furthermore, TGF-β signaling has recently been correlated with resistance against both targeted and conventional anticancer agents. Here, we present data demonstrating a role for TGF-β in chemotherapy resistance in colorectal cancer (CRC). We discuss these results in the context of recent findings indicating TGF-β signaling as an emerging player in cancer drug resistance.

Original publication




Journal article


Cell Cycle

Publication Date





2960 - 2968


EMT, TGF-β, chemotherapy, drug resistance, Antineoplastic Agents, Apoptosis, Cell Line, Tumor, Colorectal Neoplasms, Drug Resistance, Neoplasm, Epithelial-Mesenchymal Transition, Humans, Mediator Complex, RNA Interference, RNA, Small Interfering, Signal Transduction, Smad2 Protein, Smad3 Protein, Transforming Growth Factor beta